Source comparison
Comparison: AOD-9604 vs Alternative Lipolytic Compounds
AOD-9604 Beta-3 adrenergic receptor agonist (adipocyte-specific) 300–500mcg/day SC High. Targets adipose tissue only None. No GH receptor activity Ideal for fat loss research without hyperglycemia risk; short half-life requires daily dosing but minimizes syste
This comparison does not assign a generated winner or score.
- AOD-9604
- Beta-3 adrenergic receptor agonist (adipocyte-specific)
- 300–500mcg/day SC
- High. Targets adipose tissue only
- None. No GH receptor activity
- Ideal for fat loss research without hyperglycemia risk; short half-life requires daily dosing but minimizes systemic exposure
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin mimetic (pulsatile GH release)
- 100–200mcg each, 2–3×/week
- Moderate. Stimulates GH but indirectly
- Mild. Transient insulin resistance during GH pulse
- Broader anabolic effects but less selective for lipolysis; better suited for muscle preservation protocols
- Tesamorelin
- GHRH analog (stimulates endogenous GH)
- 2mg/day SC
- Moderate. Increases GH with some metabolic spillover
- Moderate. Can elevate fasting glucose in some models
- FDA-approved for lipodystrophy; more potent than AOD-9604 but higher glucose intolerance risk
- L-Carnitine
- Fatty acid transport into mitochondria
- 1–3g/day oral
- Low. Indirect metabolic support
- None
- Enhances fat oxidation only if fatty acids are already mobilized; works synergistically with lipolytic agents but ineffective alone
- Clenbuterol
- Beta-2 adrenergic agonist (thermogenic + lipolytic)
- 20–120mcg/day oral
- Low. Systemic beta-2 stimulation
- Mild. Increases insulin sensitivity acutely
- Potent fat loss but cardiovascular side effects limit use; not selective for adipose tissue
- AOD-9604 sits in a unique metabolic niche: it delivers GH-like fat loss without the GH receptor agonism that causes hyperglycemia. This makes it the most selective lipolytic peptide currently available. But only when dosed correctly and stored properly.